WO2015190439A1 - Procédé de criblage d'un composé de faible poids moléculaire capable de se lier à un anticorps - Google Patents

Procédé de criblage d'un composé de faible poids moléculaire capable de se lier à un anticorps Download PDF

Info

Publication number
WO2015190439A1
WO2015190439A1 PCT/JP2015/066498 JP2015066498W WO2015190439A1 WO 2015190439 A1 WO2015190439 A1 WO 2015190439A1 JP 2015066498 W JP2015066498 W JP 2015066498W WO 2015190439 A1 WO2015190439 A1 WO 2015190439A1
Authority
WO
WIPO (PCT)
Prior art keywords
amino acid
acid sequence
antibody
xaa
binding target
Prior art date
Application number
PCT/JP2015/066498
Other languages
English (en)
Japanese (ja)
Inventor
勘二 大島
吉田　慎一
Original Assignee
株式会社カネカ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 株式会社カネカ filed Critical 株式会社カネカ
Priority to JP2016527796A priority Critical patent/JP6532136B2/ja
Publication of WO2015190439A1 publication Critical patent/WO2015190439A1/fr

Links

Images

Classifications

    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B35/00—ICT specially adapted for in silico combinatorial libraries of nucleic acids, proteins or peptides
    • G16B35/20—Screening of libraries
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
    • G16B15/30—Drug targeting using structural data; Docking or binding prediction
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B35/00—ICT specially adapted for in silico combinatorial libraries of nucleic acids, proteins or peptides
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
    • G16C20/00—Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
    • G16C20/60—In silico combinatorial chemistry

Definitions

  • the present invention relates to a method for simply screening in silico a low molecular weight compound capable of binding to an antibody.
  • antibody drugs are one of the medical proteins that have been actively developed.
  • An antibody drug is a drug that uses an antibody as an active ingredient and uses the function of an antibody, and has reduced side effects that a conventional drug has because it works specifically with a target molecule, and High therapeutic effect can be expected.
  • Antibody drugs actually contribute to the improvement of various pathological conditions. On the other hand, since it is administered in a large amount to a living body, it is said that purity has a great influence on quality when compared with other medical proteins.
  • the molecular form of immunoglobulin G has been mainly used for antibody drugs so far.
  • IgG immunoglobulin G
  • CHO cells Chinese hamster ovary cells
  • antibody drugs that do not have an Fc region and affinity chromatography corresponding thereto have been actively developed.
  • the molecular forms of antibody drugs include those using only the variable region of the light chain of the antibody (V L ) or the variable region of the heavy chain (V H ), or the variable of the heavy chain of a camel.
  • V L variable region of the light chain of the antibody
  • V H variable region of the heavy chain
  • camel variable of the heavy chain of a camel.
  • There are various molecular forms such as those using regions (nanobody), and the development of affinity chromatography using these as target sites is still insufficient.
  • the low molecular weight compounds that have been developed so far for affinity chromatography for purifying low molecular weight antibodies include nucleotide bonds existing between the light chain and heavy chain of the antibody and the two light chains of the antibody. A depression between domains is used as a binding target site.
  • various antibody drugs have been developed, and in order to easily purify each antibody, a compound that binds to a carrier used in affinity chromatography for purification and that has a high affinity for the antibody can be easily screened. There is a need for a way to do this.
  • an object of the present invention is to provide a method for simply screening in silico a low molecular weight compound capable of binding to an antibody.
  • the inventors of the present invention have made extensive studies to solve the above problems. As a result, the specific amino acid sequence of the framework region with relatively few mutations in the variable region of the antibody is conserved in common among the antibodies. By using this sequence, low molecular weight compounds having high affinity for various antibodies can be obtained.
  • the present invention was completed by finding that it can be easily screened in silico.
  • a method for screening a low molecular weight compound that binds to an antibody In the variable region of the light chain of the antibody, the first binding target site contained in the framework region having the following amino acid sequence 1, and in the variable region of the heavy chain of the antibody, in the framework region having the amino acid sequence 2 Selecting a compound that exhibits a low docking score in a docking simulation for both of the included second binding target sites.
  • Amino acid sequence 1 In the amino acid sequence shown in SEQ ID NO: 1, Xaa at the 9th position is serine, phenylalanine, leucine, glycine, alanine or aspartic acid, and Xaa at the 15th position is proline, valine, threonine or leucine Xaa at positions 24 to 31 is any amino acid or deletion, Xaa at position 39 is glutamine, lysine, leucine or glutamic acid, and Xaa at positions 79 and 80 is any amino acid or deletion
  • Xaa at the 9th position is glycine, alanine, proline or serine
  • Xaa at the 14th position is any amino acid or deletion
  • Xaa at position 17 is glycine, alanine, serine, threonine, glutami , Glutamic acid, arginine or aspartic acid
  • Xaa at positions 41 to 43 is any amino acid or deletion
  • Xaa at position 56 is threonine, arginine, methionine, glutamic acid, lysine, asparagine or aspartic acid
  • Xaa at position 61 is leucine, alanine, valine or phenylalanine
  • Amino acid sequence wherein Xaa at position is leucine, methionine, tryptophan or isoleucine
  • Xaa at position 66 is serine, arginine, threonine, asparagine, glycine or cysteine
  • amino acid sequence 3 In the amino acid sequence shown in SEQ ID NO: 3, the amino acid sequence in which the fourth position Xaa is glutamine, lysine, leucine or glutamic acid.
  • Amino acid sequence 4 Amino acid sequence shown in SEQ ID NO: 4
  • the screening method according to the present invention involves simple screening in silico for low molecular weight compounds that bind to a carrier of affinity chromatography used for purification of various antibodies, for example, low molecular weight antibodies that do not have an Fc region. Can do.
  • the low molecular weight compounds screened by the method of the present invention are general-purpose and diverse ones showing affinity for various antibodies, so that they can be used not only for low molecular weight antibodies but also for the industrial production of immunoglobulins. It can also be used.
  • the low molecular weight compound can be used for antibody characterization, identification, quantification and the like in addition to antibody purification.
  • a low molecular weight compound (number of binding target sites: 2) having a nucleotide binding site existing between a light chain and a heavy chain as a binding target site, A low molecular weight compound (number of binding target sites: 2) having a light chain domain as a target site has been used. That is, the number of binding target sites for the antibody of the conventional low molecular weight compound is 2.
  • the low molecular weight compounds screened by the method of the present invention are present in the heavy chain and light chain constituting the antibody, respectively, and can bind to the antibody at a total of four binding target sites per antibody molecule. . Therefore, it can be said that the low molecular weight compound according to the present invention is very suitable for antibody purification and the like because it can bind to an antibody with higher affinity.
  • FIG. 1 is a diagram showing the alignment results of the VL region of the kappa chain of human antibodies.
  • FIG. 2 is a diagram showing alignment results of VH regions of human antibodies.
  • “FR” indicates a framework region
  • “CDR” indicates a complementary strand determining region.
  • a screening method for a low molecular weight compound that binds to an antibody according to the present invention includes a first binding target site contained in a framework region having amino acid sequence 1 in a variable region of a light chain of the antibody, and a heavy chain of the antibody The step of selecting a compound exhibiting a low docking score in the docking simulation for both of the second binding target sites contained in the framework region having amino acid sequence 2 in the variable region.
  • a depression (pocket) contained in the framework region is used as a binding target site for evaluating the binding ability of a low molecular compound to an antibody, particularly a human antibody.
  • the framework region refers to a region with relatively few mutations other than the complementarity determining region (CDR) in direct contact with the antigen in the variable region (V region) that is the tip of the Fab region of the antibody. It is said that the framework region has relatively few amino acid sequence variations among the variable regions, and that the three-dimensional structure is similar between antibodies.
  • CDR complementarity determining region
  • a compound showing affinity for a binding target site having a specific amino acid sequence respectively contained in the framework region in both the light chain and the heavy chain is selected.
  • the specific amino acid sequence used in the method of the present invention aligns the amino acid sequences of the framework regions of human antibodies, and forms a recess (pocket) that is relatively high in homology and into which a low molecular compound can enter. .
  • the term “alignment” refers to pair-wise alignment and multiple alignment, and refers to aligning protein amino acid sequences so that corresponding portions are aligned between two or more sequences.
  • “pair-wise alignment” refers to a sequence comparison in which the amino acid sequence to be compared and the amino acid sequence stored in the database are compared one-to-one
  • “multiple alignment” is a one-to-three or more sequence comparison. A multiple sequence comparison performed in large numbers.
  • sequence homology in two or more amino acid sequences and the like is easily calculated by software for alignment.
  • arbitrary amino acid or deletion represents a so-called “gap” corresponding to amino acid insertion / deletion in the course of evolution.
  • any amino acid 20 kinds of amino acids constituting a protein are preferable.
  • deletion indicates a single bond between amino acids before and after the chemical structure of the protein.
  • protein includes any molecule having a polypeptide structure, and includes fragmented polypeptide chains and two or more polypeptide chains linked by peptide bonds. Accordingly, in the present specification, “peptide”, “polypeptide” and “protein” are used interchangeably.
  • a “domain” is a unit of a protein's higher order structure, consisting of a sequence of tens to hundreds of amino acid residues, and sufficient for expressing any physicochemical or biochemical function. A unit.
  • sequence homology the ratio of the number of matching amino acids divided by the total number of aligned amino acids. It is expected that the higher the sequence homology, the less the mutation and the similar three-dimensional structure. In general, if there is a sequence homology of 50% or more by deletion, addition and / or substitution of one or more amino acids with respect to a certain amino acid sequence, it is expected that the three-dimensional structure is similar. If it is 40% or more, it is said that it can be used as a template for a structure for docking simulation of a low molecular compound (D. Baker & A. Sali, Science, 294, pp. 93-96 (2001)).
  • the sequence homology is as high as 50% or more, and the three-dimensional structures are very similar.
  • the amino acid sequences of the framework regions of the light and heavy chains are aligned, the sequence homology is as low as less than 30%, and generally the three-dimensional structure is not similar.
  • the sequence homology between the amino acid sequences of the binding target sites in the light chain and heavy chain framework regions of the human antibody specified in the present invention is as high as 42%, and the three-dimensional structure is likely to be similar. Accordingly, screening with the same low molecular weight compound can be performed on these binding target sites.
  • the amino acid sequence of the binding target site in the present invention is preferably the sequences shown in SEQ ID NO: 3 and SEQ ID NO: 4 for the light chain and SEQ ID NO: 5 and SEQ ID NO: 6 for the heavy chain. It is preferably 40% or more, more preferably 45% or more, and even more preferably 50% or more.
  • the amino acid sequence shown in the SEQ ID NO of the binding target site is the amino acid sequence of ⁇ chain, ⁇ chain, and two types of ⁇ chain reported as human antibodies for the light chain.
  • the screening method since the same low molecular weight compound is expected to bind if a binding target site having an amino acid sequence having a high sequence homology of 40% or more with the amino acid sequence of the binding target site of the chain is expected, the screening method in that case It is obvious that the present invention is also included in the present invention. Similarly, the present invention includes a screening method in which a binding target site is specified that increases the sequence homology of the amino acid sequence between the light and heavy chains, even if it is not a human-derived antibody.
  • a compound showing a low docking score in docking simulation is selected for both of two binding target sites having a specific amino acid sequence.
  • the computer software for performing the docking simulation for screening the low molecular weight compound is not particularly limited.
  • the software sievgene http: //www.jbic.or commonly used in in silico drug discovery. .Jp / activity / st_pr_pj / mypresto / index_mypr.html).
  • a compound docking score is obtained by docking simulation, the compounds are ranked, and a compound showing a low docking score is selected.
  • the “docking score” is a value corresponding to the binding energy between the compound and the binding target site according to the present invention. The smaller the value, the higher the affinity of the compound for the binding target site.
  • the docking score is more preferably less than ⁇ 3.0.
  • the docking score is preferably ⁇ 5.5 or more.
  • the screening method according to the present invention is a simple method using a computer, but if an unlimited compound is evaluated, the efficiency is naturally poor. Therefore, it is preferable to select the compounds to be evaluated to some extent in advance. For example, it can be selected from compounds sold by general reagent manufacturers based on solubility and the like.
  • the compound selected by the method of the present invention can be immobilized, for example, on a carrier comprising a water-insoluble substrate and used as an affinity ligand.
  • affinity ligand is a term that refers to a substance or functional group that selectively binds a target molecule from a set of molecules based on the affinity between specific molecules represented by the binding between an antigen and an antibody. In the present invention, it refers to a small molecule compound that specifically binds to a small molecule antibody and an immunoglobulin.
  • small molecule antibody refers to an antibody comprising only a partial fragment prepared from an immunoglobulin by protease degradation or genetic engineering.
  • Typical low molecular weight antibodies include Fab, single chain antibody (scFv), Diabody, and the like.
  • Fab is a molecule in which a light chain and a heavy chain are disulfide-bonded. Molecular weight is about 60 kDa
  • scFv is a light chain and heavy chain variable region linked by a short linker. Is a molecule in which two molecules of scFv are covalently associated by adjusting the length of the protein, and has two antigen-binding sites.
  • the molecules targeted by the affinity ligand in the present invention are all molecules to which the target molecule-binding domain can bind.
  • the light chain variable region (V L ) and heavy chain variable region (V H ) of an antibody Fragmented low-molecular-weight antibodies, low-molecular-weight antibody derivatives, immunoglobulin G (IgG) with various molecular forms, such as those that use only the domain (domain antibody) and those that use the variable region of the heavy chain of a camel (nanobody) And antibody derivatives.
  • examples of the “small molecule antibody derivative” include an artificial antibody obtained by fusing the Fv region and the Fc region of human IgG
  • examples of the “antibody derivative” include a part of the domain of human IgG.
  • examples include chimeric antibodies that are fused by substituting the domain of the IgG antibody of the biological species, and humanized antibodies that are fused by substituting CDRs of other IgG species (Complementarity-Determining Regions) with the CDRs of the other species antibody. It is done.
  • the affinity for low molecular weight antibodies and immunoglobulins with various molecular forms detects biosensors such as the Biacore system (GE Healthcare) using the surface plasmon resonance principle, and exothermic / endothermic changes caused by binding. It can be evaluated by a biomolecule interaction detection / analysis apparatus such as an isothermal titration calorimeter (ITC).
  • biosensors such as the Biacore system (GE Healthcare) using the surface plasmon resonance principle, and exothermic / endothermic changes caused by binding. It can be evaluated by a biomolecule interaction detection / analysis apparatus such as an isothermal titration calorimeter (ITC).
  • ITC isothermal titration calorimeter
  • the water-insoluble carrier used in the present invention preferably has a large surface area in view of the purpose and method of use of the affinity separation matrix, and is preferably a porous material having a large number of pores of an appropriate size.
  • the form of the carrier can be any of beads, monoliths, fibers, membranes (including hollow fibers), and any form can be selected. Examples of the method for immobilizing a ligand include a method in which a reactive group is introduced into a carrier and a low molecular compound is bound by a known coupling method via a linker group.
  • the reactive group examples include an amino group, a carboxy group, an ether group, and a thioether group.
  • the reactive group may be introduced by introducing a compound called “spacer”.
  • spacer a compound called “spacer”.
  • the carrier is reacted with cyanogen bromide, epichlorohydrin, diglycidyl ether, tosyl chloride, tresyl chloride, hydrazine, sodium periodate, etc., or the carrier is activated.
  • a method in which a reactive group is introduced on the surface and a low molecular compound to be immobilized as a ligand is coupled and immobilized, or a system in which a low molecular compound to be immobilized as a carrier and a ligand exists is a condensation such as carbodiimide.
  • the immobilization method include adding a reagent or a reagent having a plurality of functional groups in the molecule such as glutaraldehyde, followed by condensation and crosslinking.
  • the low molecular compound of the present invention used as a ligand may be immobilized by chemically modifying the carrier, or a spacer molecule useful for immobilization may be introduced.
  • the essence of the present invention is that the function of the low molecular weight compound is similarly imparted to the matrix in which the low molecular weight compound is immobilized as a ligand, and how the low molecular weight compound is modified / modified for immobilization. And within the scope of the present invention.
  • Purification methods for these antibodies, antibody derivatives, low-molecular-weight antibodies, and low-molecular-weight antibody derivatives can be achieved by procedures according to affinity column / chromatography purification methods using protein A columns that are already available as commercial products. (Roque ACA et al., Journal of Chromatography A, 1160, 44-55 (2007)). That is, an antibody, an antibody derivative, a low molecular antibody, and a buffer containing a low molecular antibody derivative are adjusted to be neutral, and then the solution is passed through an affinity column packed with the affinity separation matrix of the present invention. Adsorbing antibody derivatives, low molecular weight antibodies and low molecular weight antibody derivatives.
  • an appropriate amount of pure buffer is passed through the affinity column, and the inside of the column is washed.
  • the desired antibody, antibody derivative, low molecular antibody and low molecular antibody derivative are adsorbed to the affinity separation matrix of the present invention in the column.
  • an acidic buffer adjusted to an appropriate pH is passed through the column to elute the desired antibody, antibody derivative, low molecular antibody and low molecular antibody derivative, thereby achieving high purity purification.
  • a substance for promoting dissociation of the desired antibody from the matrix may be added to the acidic buffer used for elution.
  • the antibody, antibody derivative, low molecular antibody and low molecular antibody derivative adsorbed on the affinity separation matrix of the present invention can be characterized as having the binding target site.
  • the affinity separation matrix of the present invention should be washed by passing it through a pure buffer having a suitable strong acidity or strong alkalinity to such an extent that the low molecular weight compound as a ligand and the substrate of the carrier do not completely impair the function. Can be reused.
  • An appropriate denaturant or organic solvent may be added to the buffer solution.
  • the chemical stability of the ligand is expected to be higher than when a protein such as protein A is used as a ligand.
  • chemical stability means the property of retaining the function of a low molecular compound.
  • “retaining the function of a low molecular weight compound” refers to retaining affinity for a binding target site (pocket) existing in the framework region of the variable region of an immunoglobulin light chain or heavy chain. . That is, the higher the “chemical stability” of the ligand, the less the affinity to the target site decreases even when various chemical treatments are performed.
  • Example 1 Results of alignment of representative amino acid sequences of known human antibody light chain ( ⁇ chain) and heavy chain (http://www2.mrc-lmb.cam.ac.uk/vbase/alignments2.php; FIG. 1 and 2), amino acid sequences having high sequence homology in each chain were extracted and used as common amino acid sequences. Alignment of the amino acid sequences of the framework regions of the common amino acid sequences of the obtained light and heavy chains was performed, and the sequence of SEQ ID NO: 1 as the sequence common to the light chain and SEQ ID NO: 2 as the sequence common to the heavy chain Derived.
  • sequences that are exposed on the surface due to the three-dimensional structure of the antibody and that have a relatively high sequence homology were extracted.
  • the sequences in the light chain are shown in SEQ ID NO: 3 and SEQ ID NO: 4
  • the sequences in the heavy chain are shown in SEQ ID NO: 5 and SEQ ID NO: 6.
  • the sequence homology between the entire sequence including SEQ ID NO: 3 and SEQ ID NO: 4 and the entire sequence including SEQ ID NO: 5 and SEQ ID NO: 6 was 42%.
  • sequence homology between the amino acid sequence of the binding target site in the framework region of the light chain of the selected human antibody 2xa8 and the common amino acid sequence (SEQ ID NOs: 3 and 4) in the binding target site of the framework region of the light chain was 100%. It was. In addition, the sequence homology between the amino acid sequences of the light chain and heavy chain binding target sites in human antibody 2xa8 was 50%.
  • a docking simulation was conducted using 1.24 million selected compounds. The compounds were ranked according to the obtained docking scores, and the top 10,000 docking scores were selected for each binding target site.
  • Table 1 shows the docking scores and compound number distributions for the light chain and heavy chain target sites. In Table 1, the docking score corresponds to the binding energy between the compound and the binding target site, and the smaller the value, the higher the affinity with the binding target site.
  • the average docking score for both light chain and heavy chain binding target sites is within the top 10% out of a total of 20000 compounds with low docking score values for light or heavy chain binding target sites Were selected as candidate compounds. Their chemical structures are shown below.
  • Example 2 From the data registered in PDB (http://pdbj.org), which is a database of known human antibodies whose steric structure has been clarified, the above common amino acid sequence ( Search for those having 50% or more of amino acid sequence in the framework region between SEQ ID NO: 1 and SEQ ID NO: 2), and extract the three-dimensional structure of the human antibody (PDB code: 2hwz) from the extracted one downloaded.
  • PDB code: 2hwz three-dimensional structure of the human antibody
  • a depression (pocket) corresponding to the binding target site selected in Example 1 was selected as the binding target site.
  • Comparative Example 1 An example of a compound that gives a low docking score to only one of the two binding target sites of the light and heavy chains is shown in Table 4.
  • Table 4 “N / A” indicates that there is no score value because the docking scores for the binding target sites of the light and heavy chains were not included in the top 10,000.
  • the compound having an ID of NS-01599272 gave a good score for the binding target site of the light chain, but did not give a good score for the target site of the heavy chain.
  • the compound with an ID of NS-02992114 gave a good score for the heavy chain binding target site, but did not give a good score for the light chain target site. Therefore, these compounds are considered to have a lower affinity for human antibodies than the compounds selected in Examples 1 and 2 above.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Chemical & Material Sciences (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Theoretical Computer Science (AREA)
  • Evolutionary Biology (AREA)
  • Biophysics (AREA)
  • Medical Informatics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Library & Information Science (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Computing Systems (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'objectif de la présente invention est de fournir un procédé de criblage d'un composé de faible poids moléculaire capable de se lier à un anticorps in silico et dans une manière simple. Le procédé de criblage d'un composé de faible poids moléculaire capable de se lier à un anticorps selon la présente invention est caractérisé en ce qu'il comprend une étape consistant à sélectionner un composé qui présente une faible score de jonction à la fois un premier site cible de liaison et un second site cible de liaison dans une simulation de jonction, le premier site cible de liaison étant contenu dans une région de cadre qui est contenue dans une région variable à chaîne légère de l'anticorps et qui comprend la séquence d'acides aminés (1), et le second site cible de liaison étant contenu dans une région de cadre qui est contenue dans une région variable à chaîne lourde de l'anticorps et qui comprend la séquence d'acides aminés (2).
PCT/JP2015/066498 2014-06-09 2015-06-08 Procédé de criblage d'un composé de faible poids moléculaire capable de se lier à un anticorps WO2015190439A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2016527796A JP6532136B2 (ja) 2014-06-09 2015-06-08 抗体に結合する低分子化合物のスクリーニング方法

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2014-118466 2014-06-09
JP2014118466 2014-06-09

Publications (1)

Publication Number Publication Date
WO2015190439A1 true WO2015190439A1 (fr) 2015-12-17

Family

ID=54833530

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2015/066498 WO2015190439A1 (fr) 2014-06-09 2015-06-08 Procédé de criblage d'un composé de faible poids moléculaire capable de se lier à un anticorps

Country Status (2)

Country Link
JP (1) JP6532136B2 (fr)
WO (1) WO2015190439A1 (fr)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009534052A (ja) * 2006-04-24 2009-09-24 アムジェン インコーポレイテッド ヒト化ｃ−Ｋｉｔ抗体
WO2012099949A2 (fr) * 2011-01-18 2012-07-26 University Of Notre Dame Du Lac Purification d'anticorps par une chromatographie d'affinité
JP2013539354A (ja) * 2011-02-28 2013-10-24 リブゾン マブファーム インコーポレイティド 抗腫瘍壊死因子αヒト化抗体

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009534052A (ja) * 2006-04-24 2009-09-24 アムジェン インコーポレイテッド ヒト化ｃ−Ｋｉｔ抗体
WO2012099949A2 (fr) * 2011-01-18 2012-07-26 University Of Notre Dame Du Lac Purification d'anticorps par une chromatographie d'affinité
JP2013539354A (ja) * 2011-02-28 2013-10-24 リブゾン マブファーム インコーポレイティド 抗腫瘍壊死因子αヒト化抗体

Also Published As

Publication number Publication date
JPWO2015190439A1 (ja) 2017-04-20
JP6532136B2 (ja) 2019-06-19

Similar Documents

Publication Publication Date Title
Ramos‐de‐la‐Peña et al. Protein A chromatography: Challenges and progress in the purification of monoclonal antibodies
Menegatti et al. mRNA display selection and solid‐phase synthesis of Fc‐binding cyclic peptide affinity ligands
AU2012236486B2 (en) Buffer system for protein purification
JP5947802B2 (ja) ミックスモードクロマトグラフィーによる抗体捕捉の最適化方法
WO2013027796A1 (fr) Peptide de liaison à l'immunoglobuline g et procédé de détection et d'épuration d'immunoglobuline g mettant en œuvre un tel peptide
JP2019525925A (ja) アフィニティークロマトグラフィー洗浄バッファー
US20190048069A1 (en) Human antibodies that bind human tnf-alpha and methods of preparing the same
US11208436B2 (en) Populations of polypeptides having a triple-helical structure
CN116987154A (zh) 具有突变的支架的结合多肽
US20180186866A1 (en) Affinity chromatography purification with low conductivity wash buffer
KR20180034500A (ko) 친화성 크로마토그래피에서의 숙주 세포 단백질 감소 방법
CN111491951B (zh) 通过疏水相互作用色谱法耗尽轻链错配的抗体变体
Berwanger et al. Determination of the serum concentrations of the monoclonal antibodies bevacizumab, rituximab, and panitumumab using porous membranes containing immobilized peptide mimotopes
Kruljec et al. Development and characterization of peptide ligands of immunoglobulin G Fc region
Kangwa et al. An engineered Staphylococcal Protein A based ligand: Production, characterization and potential application for the capture of Immunoglobulin and Fc-fusion proteins
Xiao et al. De novo discovery of peptide-based affinity ligands for the fab fragment of human immunoglobulin G
Mustafaoglu et al. Antibody purification via affinity membrane chromatography method utilizing nucleotide binding site targeting with a small molecule
Matos et al. A purification platform for antibodies and derived fragments using a de novo designed affinity adsorbent
Kilgore et al. Development of peptide affinity ligands for the purification of polyclonal and monoclonal Fabs from recombinant fluids
WO2013125221A1 (fr) Ligand d'affinité pour la purification d'anticorps
WO2015190439A1 (fr) Procédé de criblage d'un composé de faible poids moléculaire capable de se lier à un anticorps
Bozovičar et al. Focused peptide library screening as a route to a superior affinity ligand for antibody purification
WO2024077083A2 (fr) Compositions et procédés de purification de fragments d'anticorps de liaison à l'antigène à l'aide de ligands peptidiques
US20230399358A1 (en) Immunoglobulin purification peptides and their use
WO2023064914A1 (fr) Compositions et procédés de purification de fluides biologiques

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15805907

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2016527796

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 15805907

Country of ref document: EP

Kind code of ref document: A1